---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Limitations of current therapies"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Limitations of current therapies. Topics: No curative therapy and restricted access to combination treatment, No therapy shown to reduce mortality before the LEMBAZ approval, Sponsor and investigator statements on limited options in infantile-onset disease, Evidence gaps for arimoclomol and levacetylleucine identified by the ACMG, and 3 further topics. 8 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Limitations of current therapies

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

### Summary

- No currently available therapy for NPC is curative. Before the LEMBAZ approval, two therapies were approved for NPC, and neither had been shown to reduce the risk of death.
- Age and weight limits: FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients 2 years of age or older (arimoclomol, in combination with miglustat) or weighing 15 kg or more (levacetylleucine), leaving limited options for early infantile-onset NPC. An open-label substudy of arimoclomol in infants younger than 24 months enrolled 5 participants aged 14 to 23 months, and the company anticipates filing a supplemental application for this age group in Q1 2027.
- Miglustat: miglustat is used off-label for NPC in the United States. In a comparison of 10 treated and 16 untreated individuals with early infantile NP-C, all treated patients developed loss of psychomotor acquisitions or additional neurological symptoms, and the authors report that “Miglustat allowed no significant long-term neurodevelopmental improvement nor significant increase of survival in patients with early infantile NP-C”. In a pooled observational analysis, the hazard ratio for mortality with miglustat was 0.671 in early infantile patients, a result that did not achieve statistical significance, and 0.364 (95% CI 0.165, 0.801) in late infantile patients.
- Levacetylleucine: the randomized, placebo-controlled crossover trial enrolled 60 participants with a median age of 25 years (range 5 to 67 years) and treated each period for 12 weeks; the estimated treatment difference in the fSARA total score was -0.4 (95% CI -0.7, -0.2).
- Arimoclomol: efficacy was demonstrated in patients receiving background miglustat, with a placebo-subtracted difference in the rescored 4-domain NPCCSS of -2.2 (95% CI -3.8, -0.6) at month 12. The FDA determined that evidence for arimoclomol monotherapy was insufficient, and after re-examination on 12 November 2026 the European Medicines Agency confirmed its recommendation to refuse marketing authorisation for arimoclomol (Meplyffa).
- Evidence gaps: the arimoclomol and levacetylleucine trials did not address nonneurological manifestations such as liver disease, no published studies address coadministration of the two drugs, and data beyond 5 years are extremely limited. Differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.
- Other cyclodextrin products: in the TransportNPC phase 3 trial of intravenous Trappsol Cyclo (remibetadex), the primary endpoint at Week 96 did not achieve statistical significance (p=0.19), and hearing-related adverse events occurred in 15.6% of participants receiving Trappsol Cyclo and 13.3% receiving placebo; an NDA was submitted on October 28, 2026. One analysis concluded that HPβCD remains investigational and that hearing impairment is an important safety concern.
- Supportive care: most other options are supportive in nature, and for many individuals clinical trial participation may be the only access to disease-modifying treatment.

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/); [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer); [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf); [FDA Miplyffa approval announcement (2024)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c); [Mengel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13310637/); [Zevra Therapeutics third quarter 2026 results release (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000085/zvra-20261103xex991earnings.htm); [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf); [Freihuber et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10362619/); [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/); [Aqneursa prescribing information (2026)](https://www.aqneursa.com/wp-content/prescribing-information.pdf); [Miplyffa prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214927s000lbl.pdf); [European Medicines Agency Meplyffa refusal (2026)](https://www.ema.europa.eu/en/medicines/human/EPAR/meplyffa); [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/); [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/); [Rafael Holdings TransportNPC topline results release (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026104876/ea030712501ex99-1.htm); [Rafael Holdings Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm); [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.1.7-2"></a>

### No curative therapy and restricted access to combination treatment

> “No currently available therapies for NPC are curative.”
> “Improving the accessibility and affordability of novel therapies is crucial for enhancing patient outcomes in NPC”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.7-3"></a>

### No therapy shown to reduce mortality before the LEMBAZ approval

> “Prior to this approval action, two therapies were approved for NPC, but neither has been shown to reduce the risk of death.”

Source: [FDA Lembaz approval press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer)

<a id="topic-2.2.2.1.7-4"></a>

### Sponsor and investigator statements on limited options in infantile-onset disease

> “There are limited therapies for patients with rapidly progressive and fatal infantile-onset NPC, none of which have demonstrated survival benefit”

Source: [Beren Therapeutics ACMG data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-data-supporting-the-efficacy-of-adrabetadex-in-infantile-onset-npc-at-2026-acmg-clinical-genetics-meeting/)

> “FDA-approved treatments for the neurological manifestations of NPC are indicated only for patients ≥2 years of age (arimoclomol) or ≥15 kg (levacetylleucine), leaving limited treatment options for individuals with early I-NPC.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

> “No therapies have been approved by the FDA to improve survival in NPC.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-2.2.2.1.7-5"></a>

### Evidence gaps for arimoclomol and levacetylleucine identified by the ACMG

> “Neither trial addressed nonneurological manifestations, such as liver disease.”
> “There are no published studies of outcomes or safety addressing coadministration of arimoclomol and levacetylleucine.”
> “Available data for treatment of NPC with arimoclomol or levacetylleucine beyond 5 years are extremely limited; long-term outcomes are not known.”

Source: [Rodriguez-Gil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800820/)

<a id="topic-2.2.2.1.7-6"></a>

### Evidence gaps identified in a state Medicaid drug class review

> “There is insufficient evidence of the efficacy and safety of combination therapy of arimoclomol used with levacetylleucine.”
> “There were no significant safety signals with either medication, but data is limited by small sample sizes and short study durations of placebo control.”

Source: [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf)

<a id="topic-2.2.2.1.7-7"></a>

### Limited access to disease-modifying therapy in the Australian standard of care

> “Disease‐modifying treatment options for NP‐C are limited (Table 5).”
> “For many individuals, clinical trial participation may be the only way to access disease‐modifying treatment.”
> “With no cure and limited access to disease‐modifying therapy, optimal management in Australia comprises symptomatic treatment of clinical manifestations and ongoing monitoring.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.1.7-8"></a>

### Systematic review: therapies cannot be compared directly

> “However, differences in study design, outcome measures, and follow-up preclude direct comparison between therapies.”

Source: [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
